Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
Abstract Background Telavancin—a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant Staphylococcus aureus (MRSA)—is approved in the USA for once-daily intravenous use. This registry study captured patient characteristics, prescr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2019-11-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | http://link.springer.com/article/10.1007/s40801-019-00165-8 |